Price Chart

Executive Summary

The Delaware District Court issued a Markman order in a patent case against Amgen, ruling that the claim term 'a functional CH1 domain with an antigen' in the '877 and '179 patents is indefinite, and declining to judicially correct it. This effectively invalidates certain asserted claims, removing a potential liability for Amgen. Other claim terms were construed largely in favor of the plaintiffs, so the case continues on remaining claims.

Court Ruling Details

Key Facts

• The court found the term 'a functional CH1 domain with an antigen' indefinite, denying judicial correction due to culpability and delay by plaintiffs.
• Other disputed terms (e.g., 'VH binding domain', 'heterologous', 'soluble') were construed in favor of plaintiffs, keeping those claims alive.
• The ruling is interlocutory; the case will proceed to summary judgment or trial on remaining claims.
• No damages or injunctions were awarded; the ruling only affects claim scope and validity.

Financial Impact

Not quantified in the ruling; potential liability reduction from invalidation of certain claims, but overall exposure remains uncertain.

Risk Factors

• Plaintiffs may appeal the indefinite ruling to the Federal Circuit.
• Remaining claims could still lead to infringement findings and damages.
• The court's criticism of plaintiff's conduct may not affect the merits of other claims.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 1 court opinion from CourtListener.

US Market Status